|Bid||101.56 x 800|
|Ask||103.99 x 300|
|Day's Range||102.00 - 102.47|
|52 Week Range||84.58 - 102.48|
|PE Ratio (TTM)||N/A|
|Expense Ratio (net)||0.06%|
This has been another year of brisk new product launches from the exchange-traded funds industry as hundreds of new funds have come to market. As is often the case, some new ETFs take awhile to attract ...
ETF adoption has rapidly accelerated in recent years, with many investors steering to cheap ETFs to potentially bolster long-term investment returns. There are 2,040 U.S.-listed ETFs on the market with ...
Goldman Sachs Asset Management is ramping up a price war with the pending launch of a new "smart-beta" exchange-traded fund with an expense ratio as low as 0.09% (or 9 basis points) -- a level even lower than some passive index funds, says Moody's Investors Service. Analyst Stephen Tu writes: GSAM’s move expands the ETF price war beyond plain vanilla ETFs into smart-beta ETFs, implying that the industry’s higher pricing assumptions for smart-beta products will not hold.
Zimmer Biomet registered net sales of $1.95 billion, exceeding the analysts’ estimate, and saw year-over-year sales growth of around 1.1%.
A prominent theme among U.S. equity exchange traded funds this year is the laggard status of the value factor. Just look at the Vanguard Value ETF (NYSEArca: VTV). VTV, the largest value ETF by assets, ...
In 2Q17, Merck’s (MRK) Gardasil/Gardasil 9 generated revenues of ~$469 million, which reflected ~19% growth year-over-year and ~12% growth quarter-over-quarter.
Growth stocks seem likely to keep the upper hand so long as doubts remain about the potential for Washington to come through with tax cuts and infrastructure spending that would give a boost to value.
On July 20, 2017, Abbott Laboratories (ABT) released its 2Q17 earnings. That day, ABT stock rose more than 4.0% from its closing price of $49.40 on July 19, 2017.
Of the 22 brokerage firms covering JNJ, ten (~45%) have rated the stock a “buy,” while 12 (55%) have rated it as a “hold.” None has rated the stock a “sell.”
Eli Lilly (LLY) and Merck (MRK) together conducted the KEYNOTE-021 trial for evaluation of the combination regimen in patients with NSCLC.
Abbott Laboratories (ABT) is set to release its 2Q17 results on July 20, 2017. In a Reuters survey of 19 brokerage firms, ~68% of the analysts rated Intuitive Surgical a “buy.”
JNJ reported ~$17.8 billion in revenues in 1Q17, registering a YoY sales growth of around 1.6%. Its Medical Device segment reported ~3% growth.
Zimmer Biomet Holdings (ZBH) announced a quarterly cash dividend of $0.24 per share on May 30, 2017, for 2Q17, payable on July 28, 2017.
On May 8, 2017, Abbott Laboratories (ABT) announced the CE Marking approval of its Confirm Rx ICM. ABT stock rose 0.09% that day.
In 1Q17, Baxter’s (BAX) renal segment reported revenues close to $896.0 million, which is an operational growth of around 2.0% YoY.